Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

720 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Simultaneous characterization of metabolic, cardiac, vascular and renal phenotypes of lean and obese SHHF rats.
Youcef G, Olivier A, L'Huillier CP, Labat C, Fay R, Tabcheh L, Toupance S, Rodriguez-Guéant RM, Bergerot D, Jaisser F, Lacolley P, Zannad F, Laurent Vallar, Pizard A. Youcef G, et al. Among authors: olivier a. PLoS One. 2014 May 15;9(5):e96452. doi: 10.1371/journal.pone.0096452. eCollection 2014. PLoS One. 2014. PMID: 24831821 Free PMC article.
Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study.
Olivier A, Girerd N, Michel JB, Ketelslegers JM, Fay R, Vincent J, Bramlage P, Pitt B, Zannad F, Rossignol P; EPHESUS Investigators. Olivier A, et al. Int J Cardiol. 2017 Aug 15;241:344-350. doi: 10.1016/j.ijcard.2017.02.018. Epub 2017 Feb 8. Int J Cardiol. 2017. PMID: 28284500 Clinical Trial.
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial.
Olivier A, Pitt B, Girerd N, Lamiral Z, Machu JL, McMurray JJV, Swedberg K, van Veldhuisen DJ, Collier TJ, Pocock SJ, Rossignol P, Zannad F, Pizard A. Olivier A, et al. Eur J Heart Fail. 2017 Sep;19(9):1186-1197. doi: 10.1002/ejhf.792. Epub 2017 Mar 16. Eur J Heart Fail. 2017. PMID: 28303624 Free article. Clinical Trial.
Predictors and prognostic significance of tachycardiomyopathy: insights from a cohort of 1269 patients undergoing atrial flutter ablation.
Brembilla-Perrot B, Ferreira JP, Manenti V, Sellal JM, Olivier A, Villemin T, Beurrier D, De Chillou C, Louis P, Brembilla A, Juillière Y, Girerd N. Brembilla-Perrot B, et al. Among authors: olivier a. Eur J Heart Fail. 2016 Apr;18(4):394-401. doi: 10.1002/ejhf.482. Epub 2016 Feb 1. Eur J Heart Fail. 2016. PMID: 26833591 Free article.
Risk of atrial fibrillation after atrial flutter ablation: impact of AF history, gender, and antiarrhythmic drug medication.
Brembilla-Perrot B, Girerd N, Sellal JM, Olivier A, Manenti V, Villemin T, Beurrier D, DE Chillou C, Louis P, Selton O, DE LA Chaise AT. Brembilla-Perrot B, et al. Among authors: olivier a. J Cardiovasc Electrophysiol. 2014 Aug;25(8):813-820. doi: 10.1111/jce.12413. Epub 2014 Apr 21. J Cardiovasc Electrophysiol. 2014. PMID: 24654647
Factors of negativity of electrophysiological study in children and teenagers complaining of tachycardia and prognostic significance.
Brembilla-Perrot B, Brembilla A, Moulin-Zinsch A, Sellal JM, Olivier A, Manenti V, Villemin T, Lethor JP, Taihï S, Rizk J, Rodermann M, Marçon F, Girerd N. Brembilla-Perrot B, et al. Among authors: olivier a. Pediatr Cardiol. 2015 Jan;36(1):64-70. doi: 10.1007/s00246-014-0965-8. Epub 2014 Jul 29. Pediatr Cardiol. 2015. PMID: 25070388
720 results